These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 9473741)

  • 1. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
    Minagawa Y; Kigawa J; Irie T; Kanamori Y; Itamochi H; Cheng X; Terakawa N
    Jpn J Cancer Res; 1997 Dec; 88(12):1218-23. PubMed ID: 9473741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
    Minagawa Y; Kigawa J; Itamochi H; Terakawa N
    Hum Cell; 2001 Sep; 14(3):237-43. PubMed ID: 11774743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells.
    Kikuchi Y; Hirata J; Yamamoto K; Ishii K; Kita T; Kudoh K; Tode T; Nagata I; Taniguchi K; Kuwano M
    Jpn J Cancer Res; 1997 Feb; 88(2):213-7. PubMed ID: 9119751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of DNA topoisomerases (I, II alpha, II beta) mRNA in etoposide- and mAMSA-resistant cell lines].
    Matsumoto Y; Takano H; Nagao S; Iglesias A; Fojo T
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2265-9. PubMed ID: 9422071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
    Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M
    Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
    Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
    Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
    Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
    Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
    Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
    Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
    Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
    Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
    Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
    Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA
    Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of novobiocin on cisplatin cytotoxicity and DNA interstrand cross-link formation in a cisplatin-resistant, small-cell lung carcinoma cell line.
    de Jong S; Timmer-Bosscha H; de Vries EG; Mulder NH
    Int J Cancer; 1993 Jan; 53(1):110-7. PubMed ID: 8380054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins.
    Taniguchi K; Kohno K; Kawanami K; Wada M; Kanematsu T; Kuwano M
    Cancer Res; 1996 May; 56(10):2348-54. PubMed ID: 8625310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer.
    Naniwa J; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Shimogai R; Kawaguchi W; Sato S; Terakawa N
    Int J Gynecol Cancer; 2007; 17(1):76-82. PubMed ID: 17291235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
    Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
    Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
    Utsugi T; Aoyagi K; Asao T; Okazaki S; Aoyagi Y; Sano M; Wierzba K; Yamada Y
    Jpn J Cancer Res; 1997 Oct; 88(10):992-1002. PubMed ID: 9414662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
    Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
    J Surg Oncol; 1993 Jun; 53(2):97-103. PubMed ID: 8388965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
    Chen M; Beck WT
    Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.